Medtronic Licenses Early Stage Stent Drug to Prevent Thrombosis

Medtronic has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix, for use with drug-eluting stents to prevent thrombosis.

For all the success that drug-eluting stents (DES) have had in preventing restenosis, there is increasing data showing that in a small number of patients, these implants also can produce significant adverse events resulting from late-stage thrombosis. To address that problem, Medtronic Inc. has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix Inc.

Donald J. McCaffrey, president and CEO of Calgary, Alberta-based Resverlogix, points out that the two DES currently approved for US use—the Cypher from Cordis Corp. and the Taxus from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.